Institute of Nuclear Energy Research, Atomic Energy Council, Executive Yuan, R.o.c

Atomic Energy Council-institute of Nuclear Energy Research

Institute of Nuclear Energy Research, Atomic Energy Council, Executive Yuan

Tsai-Yueh Luo

Wuu-Jyh Lin

Cheng-Fang Hsu

Show-Wen Liu

Cheng-Hsien Lin

Cheng-Liang Peng

Yu-Lung Wu

I-Chung Tang

Kwei-Luen Hsu

Te-Sheng Liang

Chang-Mau Sheng

Ching-Jun Liou

Ming-Cheng Chang

Jenn-Tzong Chen

Lie-Hang Shen

Kun-Liang Lin

Tsyh-Lang Lin

Kuan-Yin Chen

Li-Yuan Huang

Shiou-Shiow Farn

Yean-Hung Tu

Haw-Jan Chen

Kang-Wei Chang

Tse-Zung Liao

Siao-Syun Guan

Jyh-Daw Sheu

Jin-Jenn Lin

Jian-Wen Chen

Wan-I Kuo

Jian-Hua Zhao

Ying-Hsia Shih

Wei-Hsi Chen

Bor-Tsung Hsieh

Disclosed herein are a dual-targeted carbonic anhydrase IX complex, a contrast agent comprising the same, and a synthesizing method thereof. The dual-targeted carbonic anhydrase IX complex includes a carbonic anhydrase IX (CA9) binding peptide, a sulfonamide derivative, and a metal chelating agent. The dual-targeted carbonic anhydrase IX complex has potential for use as a molecular nuclear drug.

Dual-targeted carbonic anhydrase ix complex and contrast agent thereof

A method is provided to purify [F-18]FEONM under a high pressure. The synthesis processes of [F-18]FEONM are integrated. An isolation process of non-toxic radio-high performance liquid chromatography (radio-HPLC) is used to purify the crude product. The method integrates a convention [F-18]FDG synthesizer and a novel radio-HPLC system together in a heat chamber. After radiofluorinating the precursor, the reaction product is purified with an alumina solid-phase column in advance to obtain the crude product while fluorine-18 is removed. Then, diphenyl semipreparative HPLC column is used for a final purification. A non-toxic solvent is used for mobile-phase eluting to remove the unreacted precursor and the phase-transfer solvent. The radiofluorination has a reaction yield about 50 percent (%). The method has an uncorrected radiochemical yield of 10&#x2dc;20%. Both of the radio-HPLC and the radio-thin layer chromatography (radio-TLC) have radiochemical purity higher than 95%.

Method of high-pressure purification of [f-18]FEONM

The present invention provides an ophthalmic gel and a preparation method thereof. The ophthalmic gel comprises: an antibiotic; a nanocarrier, wherein the nanocarrier is used to load the antibiotic; and a biodegradable matrix, wherein the biodegradable matrix is compatible with the nanocarrier to carry the nanocarrier. When the ophthalmic gel of the present invention is applied to the surface of the cornea and conjunctiva of the eyes, the biodegradable matrix is automatically degraded and the nanocarrier carried by the biodegradable matrix will slowly release the antibiotic, loaded in the nanocarrier, at an appropriate rate to overcome the high-frequency use of general ophthalmic drugs and easily caused blurred vision; the present invention further comprises an ophthalmic gel preparation method.

Ophthalmic gel and preparation method thereof

The present invention relates to a novel use of N-(4-isopropylphenyl)-5-amino-isoindoline for diagnosing Alzheimer's disease and quantifying amyloid in the brain.

Use of N-(4-isopropylphenyl)-5-amino-isoindoline

The present invention relates to an automatic system for synthesizing iodine-123 meta-iodobenzylguanidine (I-MIBG), which comprises a first reactor for subjecting radioactive iodine-containing sodium iodide and meta-iodobenzylguanidine (MIBG) sulfate to an iodine-iodine exchange reaction to obtain radioactive iodine labeled MIBG; a purification unit for purifying the iodine labeled MIBG; and a second reactor for substituting a solvent used in purification with a phosphate buffer to obtain a phosphate solution containingI-MIBG. The present invention also relates to an automatic device for dispensingI-MIBG, which comprises the automatic system for synthesizingI-MIBG, a radioactivity measuring unit, and a dispensing and packing unit.

[object Object]

A radioactive material containing chitosan for inhibiting cancer and a preparation method thereof are revealed. The adioactive material containing chitosan is formed by using SOCTA chelating agent to connect chitosan and radionuclides such asRe, and Tc-99m etc. The preparation method of the radioactive material containing chitosan includes the steps of: prepare SOCTA-Chitosan compound; and prepare M(radionuclide)-SOCTA-Chitosan compound. By biocompatibility and clotting in alkaline environment of human blood of chitosan, the radioactive material containing chitosan is injected into cancer and staying there for a long time so as to achieve effectively treatment.

Radioactive material containing chitosan for inhibiting cancer and preparation method thereof

A radioactive mixture and a manufacturing method thereof are disclosed. The radioactive mixture (Re-MN/Lipiodol mixture) is formed by chelating reaction of MN series compounds that are amine-amide-disulfide amine quadric-dentate chelate ligands with TcO/or ReO, and then dissolved in Lipiodol. Moreover, theTc/orRe of the TcO/or ReOavoids bone marrow injuries caused by freeY. By the feature of the Lipiodol that stays in liver tumors for a long period, the radioactive mixture is applied to treat liver cancers by injection so that injuries caused by surgical operations can be prevented.Re-MN/Lipiodol is used for liver cancer, breast cancer or other solid tumors treatment. Re-188 MN or Re-188 MN/Lipiodol can be mixed with anticancer drugs, hydrogel, liposome, micelle or other nano-particles to form the multifunctional therapeutic modality.

Radioactive mixture and manufacturing method thereof

A compound containing carboxylate ester and N2S2 ligand bi-functional groups and a manufacturing method thereof are disclosed. The S in the N2S2 ligand of the compound containing carboxylate ester and N2S2 ligand bi-functional groups includes a protective group so as to avoid to be oxidized and easy storage. In a complex reaction, the protective group is automatically released As to the active carboxylate ester, it is for reacting with compounds having amino groups such as amines, amino acids, peptides, or protein etc while the N2S2 ligand is for bonding with technetium or rhenium so as to form neutral complex. The compound containing carboxylate ester and N2S2 ligand bi-functional groups is applied to radiopharmaceuticals such as contrast agents for tissues and target agents.

Compound containing carboxylate ester and N2S2 ligand bi-functional groups and manufacturing method thereof

Growing community of inventors

Taoyuan, Taiwan

Tsai-Yueh Luo